These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23203930)

  • 1. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
    Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
    J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice.
    Tanaka K; Ishikawa S; Matsui Y; Kawanishi T; Tamesada M; Harashima N; Harada M
    Cancer Immunol Immunother; 2012 Nov; 61(11):2143-52. PubMed ID: 22588648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
    Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T
    Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice.
    Wang Z; Celis E
    Cancer Immunol Immunother; 2015 Aug; 64(8):1057-66. PubMed ID: 25986168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
    Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
    Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine.
    Zhou WZ; Kaneda Y; Huang S; Morishita R; Hoon D
    Gene Ther; 1999 Oct; 6(10):1768-73. PubMed ID: 10516727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
    Steitz J; Tormo D; Schweichel D; Tüting T
    Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
    Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
    Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells.
    Muraoka D; Kato T; Wang L; Maeda Y; Noguchi T; Harada N; Takeda K; Yagita H; Guillaume P; Luescher I; Old LJ; Shiku H; Nishikawa H
    J Immunol; 2010 Sep; 185(6):3768-76. PubMed ID: 20733202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
    Rossi GR; Mautino MR; Unfer RC; Seregina TM; Vahanian N; Link CJ
    Cancer Res; 2005 Nov; 65(22):10555-61. PubMed ID: 16288048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent allorecognition has a limited impact on posttransplant vaccination.
    Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A
    J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.
    Näslund TI; Gehrmann U; Qazi KR; Karlsson MC; Gabrielsson S
    J Immunol; 2013 Mar; 190(6):2712-9. PubMed ID: 23418627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
    Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
    Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.